Another study highlighted the role of HBx in augmenting TRERNA1 expression, which subsequently reduces the sensitivity of HCC cells to sorafenib by triggering the RAS/Raf/MEK/ERK pathway. This evidence concerns the gene TRERNA1 and hepatocellular carcinoma.